Medincell stock plunges 22% in three months and breaks through its support levels
The Montpellier-based biopharmaceutical company continues its decline in mid-session on Tuesday, September 15, 2026, in a Paris market that is itself oriented downward. The stock is thus accelerating a negative momentum initiated several weeks ago, moving the price away from its main technical reference points.
A monthly decline of nearly 12% that widens the gap from moving averages
Medincell is down 2.57% during the session, at 21.22 €, while the CAC 40 and SBF 120 each decline by approximately 0.75%. The stock ranks among the largest declines in the SBF 120, in an index already under pressure. Over the week, the decline reaches nearly 7%, and over one month it exceeds 11%, confirming a selling trend that has taken hold: over three months, the cumulative loss approaches 22.6%.
The price is now significantly below its three moving averages: the MA20 at 23.62 €, the MA50 at 24.95 € and the MA200 at 25.10 € are all above the current price, with gaps ranging between 10% and over 15%. This progressive breakdown below all these benchmarks reflects a degraded configuration across multiple timeframes. The previous technical support level at 24.10 € had already been broken at the end of August, which paved the way for current levels.
An RSI in oversold territory at 27 and a macro context weighing on risky assets
The RSI stands at 27, in oversold territory, while the MACD remains negative (histogram at -0.20), two signals that reflect persistent selling pressure without any identified technical rebound at present. The next resistance level is located at 25.42 €, approximately 20% above the current price. In the background, the session is taking place in a tense macro context: the Federal Reserve is widely expected to raise its policy rate starting tomorrow, for the first time in three years, with an approximately 90% probability of a 25 basis point increase. The 10-year Treasury yield has surpassed 5%, a high since October 2023, intensifying pressure on all risky assets.
This climate unfavorable to small and mid caps with strong growth profiles compounds the difficulties specific to the stock. Furthermore, the appointment of a new medical director in early September, coming from Grünenthal, was not sufficient to reverse the trend. The price is now well below the previous support threshold at 21.76 €, thus breaking downward through a closely monitored benchmark.
